The chapter delves into the relationship between LDL cholesterol levels and plaque burden, emphasizing the importance of addressing metabolic issues through diet and lifestyle changes. The discussion involves the involvement of ApoB-containing particles in atherosclerotic plaque formation and debates the decision to lower ApoB levels without clear downsides. The chapter also explores the complexities of lowering LDL levels, highlighting the need to consider individual metabolic health in the risk-benefit calculation.
Today, Paul and Mike unpack their opinions about lipids. They talk about true risk for cardiovascular disease, primary versus secondary prevention, lipid lowering drugs, and share their thoughts on a recent podcast episode with Peter Attia.
*Produced by Mountain Valley Media
00:06:08 Blood markers & imaging techniques of metabolic function
00:14:38 Gene mutations
00:20:28 LDL & Plaque burden
00:27:23 Money in statins
00:31:38 Downsides of lowering LDL
01:21:23 The downsides of popular cholesterol lowering drugs
01:41:07 Should we fear heart attacks?
01:45:23 PCSK9 Inhibitors
01:52:43 Risk profile of Statins
01:53:02 Risk vs. reward of Ezetimibe
02:04:02 Primary vs. secondary prevention
Resources:
Debunking Sugar Claims: What Dr. Lustig Got Wrong On The Huberman Podcast:
https://www.youtube.com/watch?v=JcEmSgbMfco&t=2933s
Work With Mike: https://mikefave.com/